Can Allogene’s PD1 TurboCAR Overcome the TME? CRISPR Tx’s CTX130 CD70 KO Prevents CAR-T Exhaustion; Can TCR2’s CD70 and Allogeneic TRuC-Ts Outclass CAR-T Therapies? AACR 2021 Day 2
Here is a brief preview of this blast: On the second day of AACR 2021 Week I, four key preclinical updates were presented from Allogene, CRISPR Therapeutics, and TCR2 Therapeutics. Below, Celltelligence provides insights and context for each presentation.